Literature DB >> 21333738

Intercalation of XR5944 with the estrogen response element is modulated by the tri-nucleotide spacer sequence between half-sites.

Neil Sidell1, Raveendra I Mathad, Feng-jue Shu, Zhenjiang Zhang, Caleb B Kallen, Danzhou Yang.   

Abstract

DNA-intercalating molecules can impair DNA replication, DNA repair, and gene transcription. We previously demonstrated that XR5944, a DNA bis-intercalator, specifically blocks binding of estrogen receptor-α (ERα) to the consensus estrogen response element (ERE). The consensus ERE sequence is AGGTCAnnnTGACCT, where nnn is known as the tri-nucleotide spacer. Recent work has shown that the tri-nucleotide spacer can modulate ERα-ERE binding affinity and ligand-mediated transcriptional responses. To further understand the mechanism by which XR5944 inhibits ERα-ERE binding, we tested its ability to interact with consensus EREs with variable tri-nucleotide spacer sequences and with natural but non-consensus ERE sequences using one dimensional nuclear magnetic resonance (1D (1)H NMR) titration studies. We found that the tri-nucleotide spacer sequence significantly modulates the binding of XR5944 to EREs. Of the sequences that were tested, EREs with CGG and AGG spacers showed the best binding specificity with XR5944, while those spaced with TTT demonstrated the least specific binding. The binding stoichiometry of XR5944 with EREs was 2:1, which can explain why the spacer influences the drug-DNA interaction; each XR5944 spans four nucleotides (including portions of the spacer) when intercalating with DNA. To validate our NMR results, we conducted functional studies using reporter constructs containing consensus EREs with tri-nucleotide spacers CGG, CTG, and TTT. Results of reporter assays in MCF-7 cells indicated that XR5944 was significantly more potent in inhibiting the activity of CGG- than TTT-spaced EREs, consistent with our NMR results. Taken together, these findings predict that the anti-estrogenic effects of XR5944 will depend not only on ERE half-site composition but also on the tri-nucleotide spacer sequence of EREs located in the promoters of estrogen-responsive genes.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21333738      PMCID: PMC3072055          DOI: 10.1016/j.jsbmb.2011.02.003

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  19 in total

1.  How is tamoxifen's action subverted?

Authors:  V C Jordan
Journal:  J Natl Cancer Inst       Date:  2000-01-19       Impact factor: 13.506

Review 2.  Estrogen receptor interaction with estrogen response elements.

Authors:  C M Klinge
Journal:  Nucleic Acids Res       Date:  2001-07-15       Impact factor: 16.971

3.  The tri-nucleotide spacer sequence between estrogen response element half-sites is conserved and modulates ERalpha-mediated transcriptional responses.

Authors:  Feng-Jue Shu; Neil Sidell; Danzhou Yang; Caleb B Kallen
Journal:  J Steroid Biochem Mol Biol       Date:  2010-04-18       Impact factor: 4.292

4.  Comparison of transcriptional synergy of estrogen receptors alpha and beta from multiple tandem estrogen response elements.

Authors:  V V Tyulmenkov; S C Jernigan; C M Klinge
Journal:  Mol Cell Endocrinol       Date:  2000-07-25       Impact factor: 4.102

Review 5.  Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response.

Authors:  Rachel Schiff; Suleiman Massarweh; Jiang Shou; C Kent Osborne
Journal:  Clin Cancer Res       Date:  2003-01       Impact factor: 12.531

6.  Novel DNA bis-intercalation by MLN944, a potent clinical bisphenazine anticancer drug.

Authors:  Jixun Dai; Chandanamalie Punchihewa; Prakash Mistry; Aik Teong Ooi; Danzhou Yang
Journal:  J Biol Chem       Date:  2004-08-17       Impact factor: 5.157

7.  Tamoxifen resistance by a conformational arrest of the estrogen receptor alpha after PKA activation in breast cancer.

Authors:  Rob Michalides; Alexander Griekspoor; Astrid Balkenende; Desiree Verwoerd; Lennert Janssen; Kees Jalink; Arno Floore; Arno Velds; Laura van't Veer; Jacques Neefjes
Journal:  Cancer Cell       Date:  2004-06       Impact factor: 31.743

8.  Interplay between estrogen response element sequence and ligands controls in vivo binding of estrogen receptor to regulated genes.

Authors:  Adam J Krieg; Sacha A Krieg; Bonnie S Ahn; David J Shapiro
Journal:  J Biol Chem       Date:  2003-11-14       Impact factor: 5.157

9.  Two estrogen response element sequences near the PCNA gene are not responsible for its estrogen-enhanced expression in MCF7 cells.

Authors:  Cheng Wang; Jie Yu; Caleb B Kallen
Journal:  PLoS One       Date:  2008-10-24       Impact factor: 3.240

10.  Genomic analysis of estrogen cascade reveals histone variant H2A.Z associated with breast cancer progression.

Authors:  Sujun Hua; Caleb B Kallen; Ruby Dhar; Maria T Baquero; Christopher E Mason; Beth A Russell; Parantu K Shah; Jiang Liu; Andrey Khramtsov; Maria S Tretiakova; Thomas N Krausz; Olufunmilayo I Olopade; David L Rimm; Kevin P White
Journal:  Mol Syst Biol       Date:  2008-04-15       Impact factor: 11.429

View more
  6 in total

1.  Bisphenol-A induces expression of HOXC6, an estrogen-regulated homeobox-containing gene associated with breast cancer.

Authors:  Imran Hussain; Arunoday Bhan; Khairul I Ansari; Paromita Deb; Samara A M Bobzean; Linda I Perrotti; Subhrangsu S Mandal
Journal:  Biochim Biophys Acta       Date:  2015-02-25

Review 2.  DNA Recognition by a Novel Bis-Intercalator, Potent Anticancer Drug XR5944.

Authors:  Clement Lin; Danzhou Yang
Journal:  Curr Top Med Chem       Date:  2015       Impact factor: 3.295

3.  PLIP 2021: expanding the scope of the protein-ligand interaction profiler to DNA and RNA.

Authors:  Melissa F Adasme; Katja L Linnemann; Sarah Naomi Bolz; Florian Kaiser; Sebastian Salentin; V Joachim Haupt; Michael Schroeder
Journal:  Nucleic Acids Res       Date:  2021-07-02       Impact factor: 16.971

4.  Solution structure of a 2:1 complex of anticancer drug XR5944 with TFF1 estrogen response element: insights into DNA recognition by a bis-intercalator.

Authors:  Clement Lin; Raveendra I Mathad; Zhenjiang Zhang; Neil Sidell; Danzhou Yang
Journal:  Nucleic Acids Res       Date:  2014-04-07       Impact factor: 16.971

Review 5.  Targeting Transcription Factors for Cancer Treatment.

Authors:  Mélanie Lambert; Samy Jambon; Sabine Depauw; Marie-Hélène David-Cordonnier
Journal:  Molecules       Date:  2018-06-19       Impact factor: 4.411

Review 6.  Novel DNA Bis-Intercalator XR5944 as a Potent Anticancer Drug-Design and Mechanism of Action.

Authors:  Adam J Buric; Jonathan Dickerhoff; Danzhou Yang
Journal:  Molecules       Date:  2021-07-07       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.